| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
N1,N10-Bis(p-coumaroyl)spermidine exhibits inhibitory effects on alpha-glucosidase. It may target alpha-glucosidase, an enzyme involved in carbohydrate digestion. Its mechanism involves inhibition of alpha-glucosidase activity, which may have implications for glucose metabolism and diabetes research.
|
|---|---|
| ln Vitro |
In vitro, N1,N10-Bis(p-coumaroyl)spermidine is inhibitory to alpha-glucosidase. It can be extracted from the herb of alfalfa. It is a phenylpropanoid with potential antidiabetic activity through alpha-glucosidase inhibition.
|
| ln Vivo |
In vivo studies for N1,N10-Bis(p-coumaroyl)spermidine are limited. Its alpha-glucosidase inhibitory activity suggests potential for reducing postprandial blood glucose levels. Animal studies are needed to confirm its in vivo efficacy and safety for diabetes management.
|
| Enzyme Assay |
Cell-free assays for N1,N10-Bis(p-coumaroyl)spermidine: alpha-glucosidase inhibition is measured using p-nitrophenyl-α-D-glucopyranoside as substrate. The compound is incubated with alpha-glucosidase and substrate in buffer at 37°C for 10-30 minutes. Absorbance is measured at 405 nm. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for N1,N10-Bis(p-coumaroyl)spermidine: intestinal epithelial cells (e.g., Caco-2 cells) are cultured and treated with the compound at concentrations of 0.1-100 µM. Alpha-glucosidase activity is measured in cell lysates. Glucose uptake and transport are assessed. Cell viability is measured by MTT assay.
|
| Animal Protocol |
In vivo animal studies for N1,N10-Bis(p-coumaroyl)spermidine: diabetic rodent models (e.g., streptozotocin-induced diabetic mice) would be used. Animals are administered the compound orally at doses of 10-50 mg/kg. Blood glucose levels are monitored after carbohydrate loading. Alpha-glucosidase activity is measured in intestinal tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N1,N10-Bis(p-coumaroyl)spermidine: as a small molecule (molecular weight 437.53), it may have moderate oral bioavailability. It is likely metabolized in the liver and excreted via the kidneys. Tissue distribution and elimination pathways require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicity of N1,N10-Bis(p-coumaroyl)spermidine: comprehensive toxicity data are limited. As a natural phenylpropanoid, it is generally considered safe at moderate doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
N(1),N(8)-bis(coumaroyl)spermine is a secondary amino compound, which is the product of the monoacylation of the primary amino group of spermine with trans-coumaric acid. It is a plant metabolite. It is an enamide, polyphenol, secondary amino compound, and secondary carboxamide. It is functionally related to spermine and trans-4-coumaric acid. It is the conjugate base of N(1),N(8)-bis(coumaroyl)spermine (1+).
N1,N10-bis(p-coumaryl)spermine has been reported in Aphelandra tetragona, and relevant data are available. N1,N10-Bis(p-coumaroyl)spermidine is a research compound with potential applications in diabetes and metabolic research. It is available as a reference standard for pharmacological studies. Its mechanism involves alpha-glucosidase inhibition. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C25H31N3O4
|
|---|---|
| Molecular Weight |
437.53
|
| Exact Mass |
437.231
|
| CAS # |
114916-05-1
|
| PubChem CID |
15270795
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
776.2±60.0 °C at 760 mmHg
|
| Flash Point |
423.2±32.9 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.626
|
| LogP |
2.32
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
32
|
| Complexity |
592
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(/C(/[H])=C(\[H])/C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(/C(/[H])=C(\[H])/C1C([H])=C([H])C(=C([H])C=1[H])O[H])=O
|
| InChi Key |
QYBCBMVQSCJMSA-VOMDNODZSA-N
|
| InChi Code |
InChI=1S/C25H31N3O4/c29-22-10-4-20(5-11-22)8-14-24(31)27-18-2-1-16-26-17-3-19-28-25(32)15-9-21-6-12-23(30)13-7-21/h4-15,26,29-30H,1-3,16-19H2,(H,27,31)(H,28,32)/b14-8+,15-9+
|
| Chemical Name |
(E)-3-(4-hydroxyphenyl)-N-[4-[3-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]amino]propylamino]butyl]prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2856 mL | 11.4278 mL | 22.8556 mL | |
| 5 mM | 0.4571 mL | 2.2856 mL | 4.5711 mL | |
| 10 mM | 0.2286 mL | 1.1428 mL | 2.2856 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
